×
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NASDAQ:NERV

Minerva Neurosciences News Headlines

$3.42
-0.02 (-0.58%)
(As of 06/29/2022 05:49 PM ET)
Add
Compare
Today's Range
$3.34
$3.54
50-Day Range
$2.70
$5.60
52-Week Range
$2.62
$19.28
Volume
26,435 shs
Average Volume
19,885 shs
Market Capitalization
$18.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00
Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

NERV Media Mentions By Week

NERV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NERV
News Sentiment

0.35

0.40

Average
Medical
News Sentiment

NERV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NERV Articles
This Week

3

0

NERV Articles
Average Week



NERV Stock News Headlines Today

SourceHeadline
marketbeat.com logoStockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)
marketbeat.com - June 22 at 1:29 AM
MarketBeat logoMinerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com
americanbankingnews.com - June 24 at 4:10 AM
finance.yahoo.com logoHere's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
finance.yahoo.com - June 22 at 12:06 PM
marketwatch.com logoMinerva Neurosciences Shares Slip After Reverse Split >NERV
marketwatch.com - June 21 at 10:16 AM
MarketBeat logoMinerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com
americanbankingnews.com - June 15 at 3:24 AM
MarketBeat logoZacks Investment Research Upgrades Minerva Neurosciences (NASDAQ:NERV) to Hold
americanbankingnews.com - June 9 at 4:50 AM
MarketBeat logoMinerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com
americanbankingnews.com - June 6 at 1:40 AM
finanznachrichten.de logoMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
finanznachrichten.de - May 6 at 6:06 AM
seekingalpha.com logoMinerva Neurosciences GAAP EPS of -$0.23 misses by $0.05
seekingalpha.com - May 4 at 11:46 AM
finance.yahoo.com logoMinerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
finance.yahoo.com - May 4 at 11:46 AM
finance.yahoo.com logoMinerva Neurosciences, Inc. (NERV)
finance.yahoo.com - May 3 at 10:51 PM
uk.investing.com logoMinerva Outlines Next Steps For US Application For Schizophrenia Candidate
uk.investing.com - April 7 at 3:47 PM
seekingalpha.com logoMinerva gets FDA meeting minutes on its treatment for negative symptoms in schizophrenia
seekingalpha.com - April 7 at 10:46 AM
finance.yahoo.com logoMinerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
finance.yahoo.com - April 7 at 10:46 AM
finance.yahoo.com logoMarinus (MRNS) Gets FDA Nod for Ztalmy in Rare Genetic Disorder
finance.yahoo.com - March 21 at 1:35 PM
benzinga.com logoHC Wainwright & Co. Maintains Buy on Minerva Neurosciences, Lowers Price Target to $5
benzinga.com - March 4 at 5:37 PM
seekingalpha.com logoMinerva Neurosciences GAAP EPS of -$0.50 misses by $0.31
seekingalpha.com - March 1 at 3:35 PM
finance.yahoo.com logoMinerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
finance.yahoo.com - March 1 at 3:35 PM
finance.yahoo.com logoMinerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 1 at 3:35 PM
finanznachrichten.de logoMinerva Neurosciences, Inc: Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
finanznachrichten.de - February 28 at 10:41 AM
finance.yahoo.com logoMinerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin
finance.yahoo.com - February 28 at 10:41 AM
thestreet.com logoMinerva Neurosciences (NERV) Stock Price Target Hiked at Jefferies
thestreet.com - January 21 at 6:11 PM
nasdaq.com logoWill Minerva Neurosciences (NASDAQ:NERV) Spend Its Cash Wisely?
nasdaq.com - December 25 at 1:05 PM
finance.yahoo.com logoIs Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?
finance.yahoo.com - December 1 at 8:54 AM
msn.com logoMinerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue Estimates
msn.com - November 8 at 10:40 AM
finance.yahoo.com logoMinerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission
finance.yahoo.com - November 3 at 9:02 AM
finanznachrichten.de logoMinerva Neurosciences, Inc: Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
finanznachrichten.de - November 2 at 8:21 PM
finance.yahoo.com logoMinerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8
finance.yahoo.com - November 1 at 8:54 AM
markets.businessinsider.com logoMinerva Neurosciences, Inc : Minerva Neurosciences Announces Promotion of Geoff Race to President
markets.businessinsider.com - October 12 at 11:19 PM
finanznachrichten.de logoMinerva Neurosciences, Inc: Minerva Neurosciences Announces Promotion of Geoff Race to President
finanznachrichten.de - October 11 at 10:13 AM
finance.yahoo.com logoMinerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations
finance.yahoo.com - September 30 at 5:53 PM
msn.com logoBRIEF-Minerva Neurosciences Reports Update On Roluperidone for Treatment of Negative Symptoms of Schizophrenia
msn.com - September 30 at 12:53 PM
finance.yahoo.com logoMinerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
finance.yahoo.com - September 30 at 12:53 PM
finance.yahoo.com logoImplied Volatility Surging for Minerva Neurosciences (NERV) Stock Options
finance.yahoo.com - September 27 at 10:36 AM
nz.finance.yahoo.com logoMinerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
nz.finance.yahoo.com - September 8 at 2:42 PM
finance.yahoo.com logoMinerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development
finance.yahoo.com - September 8 at 2:41 PM
finance.yahoo.com logoMinerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates
finance.yahoo.com - August 2 at 10:08 AM
finance.yahoo.com logoMinerva Neurosciences (NERV) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 2 at 10:08 AM
markets.businessinsider.com logoMinerva Neurosciences earnings: here's what Wall Street expects
markets.businessinsider.com - July 31 at 4:38 PM
finance.yahoo.com logoAnalysts Estimate Minerva Neurosciences (NERV) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 26 at 7:15 PM
finance.yahoo.com logoMinerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021
finance.yahoo.com - July 26 at 9:01 AM
nasdaq.com logoMinerva Neurosciences, Inc Common Stock (NERV)
nasdaq.com - July 23 at 7:12 PM
markets.businessinsider.com logoMinerva Neurosciences, Inc : Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
markets.businessinsider.com - June 18 at 10:56 PM
marketwatch.com logoInsomnia Drugs Market 2021: Industry Growth with Emerging Trends, Top Countries Data, Opportunities and Forecast 2026
marketwatch.com - May 31 at 8:44 AM
finance.yahoo.com logoMinerva Neurosciences (NERV) Enters Overbought Territory
finance.yahoo.com - May 19 at 7:19 AM
markets.businessinsider.com logoMinerva Neurosciences, Inc : Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates
markets.businessinsider.com - May 14 at 9:21 AM
msn.com logoWhy Minerva Neurosciences' Stock Is Trading Higher Today
msn.com - May 12 at 6:17 PM
baystreet.ca logoMinerva Leaps on Results
baystreet.ca - May 12 at 1:11 PM
msn.com logoThe Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
msn.com - May 12 at 1:11 PM
msn.com logoMinerva Shares Soar on Positive Schizophrenia Drug Trial
msn.com - May 12 at 1:11 PM
finance.yahoo.com logoMinerva (NERV) Soars on Promising Schizophrenia Study Data
finance.yahoo.com - May 12 at 1:11 PM
Get Minerva Neurosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:NERV) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.